US EditionUS Obesity Rates Have Dropped, And GLP-1 Drugs May Explain Why
3 Articles
3 Articles
US Obesity Rates Have Dropped, And GLP-1 Drugs May Explain Why
There's some good news regarding obesity rates in the US: New survey data shows 37 percent of US adults are currently classed as obese, down from a record high of 39.9 percent in 2022. And there seems to be one major reason why. The findings are based on an online survey of 16,946 US adults conducted by the data analytics firm Gallup in the first three quarters of 2025. This equates to around 7.6 million fewer people being counted as obese compa…
JCI Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders. Acute and chronic activation of GLP-1 receptor signaling also reduces systemic and tissue inflammation in mice and humans, throug…
Berlin – Acute ischemic stroke (AIS) is associated with high rates of disability and mortality worldwide. Approximately 15% of stroke survivors have diabetes mellitus, and 60% are overweight or obese. These comorbidities increase the risk of further cardiovascular events, including recurrent stroke.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
